Status:
NOT_YET_RECRUITING
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Renal Injury
Acute Kidney Injury
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.
Detailed Description
This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients undergoing a CABG, AVR, or CABG/AVR. Kidney injury biomarkers NGAL, Uromodulin, and Hepc...
Eligibility Criteria
Inclusion
- Adult patients undergoing cardiopulmonary bypass
- Procedure coronary artery bypass grafting, aortic valve replacement, or both
Exclusion
- Patients \< 18 years old
- Emergent surgery
- Preoperative kidney disease (Cr \> 2.0 or on renal replacement therapy)
- Ejection fraction \< 40%
- Incomplete data in medical record
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06109714
Start Date
September 1 2025
End Date
December 31 2028
Last Update
May 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.